NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 Novembro 2023 - 10:00AM
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, announced today that, the
United States Patent and Trademark Office (“USPTO”) issued a Notice
of Allowance for U.S. Patent Application 16/812,702, titled
“Agent-Delivering Neural Probe Devices and Related Systems and
Methods,” which covers novel electrodes that can operate as a
standard neural electrode that also delivers a treatment agent to a
target area of the patient’s brain.
A Notice of Allowance is issued by the USPTO
after examination of a patent application and a determination that
a patent should be granted from the application. NeuroOne
anticipates the issuance of the patent in the coming months.
In addition to this allowed patent application,
NeuroOne’s patent portfolio includes the two other allowed patent
applications, one issued U.S. patent, eight pending U.S.
applications, and several foreign applications covering a wide
variety of thin-film electrode technologies, including both neural
and spinal cord electrodes with unique structures that optimize the
functionality and minimized profile of those electrodes.
Dave Rosa, CEO of NeuroOne, commented, “The
Company continues to strengthen its existing patent portfolio with
this recent notification by the USPTO. These allowances are
especially important as we advance our efforts to partner with
existing biopharma companies to offer the next combination device
that can provide both drug delivery and sEEG recording
capabilities.”
About NeuroOne
NeuroOne Medical Technologies Corporation is a
developmental stage company committed to providing minimally
invasive and hi-definition solutions for EEG recording, brain
stimulation and ablation solutions for patients suffering from
epilepsy, Parkinson's disease, dystonia, essential tremors, chronic
pain due to failed back surgeries, and other related neurological
disorders that may improve patient outcomes and reduce procedural
costs. The Company may also pursue applications for other areas
such as depression, mood disorders, pain, incontinence, high blood
pressure, and artificial intelligence. For more information, visit
nmtc1.com.
Forward Looking Statements
This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any
information contained in this presentation may be a forward–looking
statement that reflects NeuroOne’s current views about future
events and are subject to known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of
activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking
statements by the words or phrases "may," "might," "will," "could,"
"would," "should," "expect," "intend," "plan," "objective,"
"anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue, "focused
on," "committed to" and "ongoing," or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Forward–looking statements may include statements
regarding the development of the Company's electrode technology
program, applications for, or receipt of, regulatory clearance, the
receipt and/or timing of additional feedback from the FDA relating
to the Company’s OneRF ablation system, the receipt and/or timing
of regulatory approval of the Company’s OneRF ablation system, the
ability of the OneRF ablation system to offer a safer option for
patients, the timing and extent of product launch and
commercialization of our technology, clinical and pre-clinical
testing, what the future may hold for electrical stimulation and
NeuroOne's potential role, business strategy, market size,
potential growth opportunities, future operations, future
efficiencies, and other financial and operating information.
Although NeuroOne believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our partnerships may not facilitate the
commercialization or market acceptance of our technology; whether
due to supply chain disruptions, labor shortages, risks that our
technology will not perform as expected based on results of our
pre-clinical and clinical trials; risks related to uncertainties
associated with the Company's capital requirements to achieve its
business objectives and ability to raise additional funds: the risk
that we may not be able to secure or retain coverage or adequate
reimbursement for our technology; uncertainties inherent in the
development process of our technology; risks related to changes in
regulatory requirements or decisions of regulatory authorities;
that we may not have accurately estimated the size and growth
potential of the markets for our technology; risks relate to
clinical trial patient enrollment and the results of clinical
trials; that we may be unable to protect our intellectual property
rights; and other risks, uncertainties and assumptions, including
those described under the heading "Risk Factors" in our filings
with the Securities and Exchange Commission. These forward–looking
statements speak only as of the date of this press release and
NeuroOne undertakes no obligation to revise or update any
forward–looking statements for any reason, even if new information
becomes available in the future.
Contact:800-631-4030 ir@nmtc1.com
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024